{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:36:24Z","timestamp":1789133784717,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravitreal anti\u2011VEGF therapy is effective, yet real\u2011world outcomes are limited by non persistence. We investigated patient\u2011reported reasons for discontinuation under pro-re-nata therapy protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This ambispective real-world study at a German eye hospital evaluated patients receiving intravitreal therapy for diabetic macular edema (DME), retinal vein occlusion (RVO), or neovascular age related macular degeneration (nAMD) using the pro re nata (PRN) protocol. Patient records were reviewed, and those meeting lost to follow up (LTFU) criteria (no injections or visits within 3\u2009months) were contacted via written letter and phone. When patients were reached surveys to assess reasons for LTFU, perceived treatment burden, mobility, and comorbidities were completed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 657 cases, 347 (52.8%) met the LTFU- criteria, 25 of which were medically indicated. Despite multiple attempts, contact and data collection was successful for only 39 patients (response rate: 12%), major part was unwilling or unable to participate. The most common reasons for discontinuation were subjective lack of treatment need (56%), perception of being \u201cfully treated\u201d (33%), fear of injections (26%), travel difficulties (28%), and time burden (15%). Despite these barriers, 52% of patients reported that the treatment was \u201cnot burdensome at all,\u201d while 3 patients (8%) continued therapy elsewhere.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this exploratory, single-centre cohort, a significant portion of patients had effectively disengaged from IVI care and were unreceptive to delayed outreach. Outcome-related perceptions and organizational hurdles were key, actionable barriers. Future strategies to improve adherence should focus on proactive follow-ups shortly after therapy discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00808-3","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:47:45Z","timestamp":1770817665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lost to follow-up while undergoing intravitreal injection therapy: barriers to adherence in a real-world setting"],"prefix":"10.1186","volume":"12","author":[{"given":"Annika","family":"Licht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis","family":"Mavris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Latz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander K.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina A.","family":"Ponto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Mirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"808_CR1","doi-asserted-by":"crossref","unstructured":"Framme C, Eter N, Hamacher T, Hasanbasic Z, Jochmann C, Johnson KT, et al. Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany: twelve-month outcomes of PERSEUS. Ophthalmol Retina. 2018;2:539\u201349","DOI":"10.1016\/j.oret.2017.09.017"},{"key":"808_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12886-018-1016-7","volume":"19","author":"L Gao","year":"2019","unstructured":"Gao L, Zhou L, Tian C, Li N, Shao W, Peng X, et al. Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: a meta-analysis. BMC Ophthalmol. 2019;19:8","journal-title":"BMC Ophthalmol"},{"key":"808_CR3","doi-asserted-by":"crossref","unstructured":"Lee M, You M. Avoidance of healthcare utilization in South Korea during the coronavirus disease 2019 (COVID-19) pandemic. Int J Environ Res Public Health. 2021;18","DOI":"10.3390\/ijerph18084363"},{"key":"808_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ceo.12696","volume":"44","author":"DSW Ting","year":"2016","unstructured":"Ting DSW, Cheung GCM, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol. 2016;44:260\u201377","journal-title":"Clin Exp Ophthalmol"},{"key":"808_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S151611","volume":"12","author":"C Ehlken","year":"2018","unstructured":"Ehlken C, Helms M, B\u00f6hringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2018;12:13\u201320","journal-title":"Clin Ophthalmol"},{"key":"808_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00347-020-01273-5","volume":"118","author":"A Lommatzsch","year":"2021","unstructured":"Lommatzsch A, Eter N, Ehlken C, Lanzl I, Kaymak H, Schuster AK, et al. Adh\u00e4renz bei der Anti-VEGF-Therapie - \u00dcberlegungen und praktische Empfehlungen. Der Ophthalmologe. 2021;118:801\u201309","journal-title":"Der Ophthalmologe"},{"key":"808_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13643-023-02261-x","volume":"12","author":"H Shahzad","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, Hubbard J, Haque S, Paudyal V, et al. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Systematic Rev. 2023;12:92","journal-title":"Systematic Rev"},{"key":"808_CR8","doi-asserted-by":"publisher","first-page":"e0314167","DOI":"10.1371\/journal.pone.0314167","volume":"19","author":"IB Pfister","year":"2024","unstructured":"Pfister IB, Schild C, Garweg JG. Predicting long-term functional anti-VEGF treatment outcomes in neovascular AMD in a real-world setting. PLoS One. 2024;19:e0314167","journal-title":"PLoS One"},{"key":"808_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00347-021-01454-w","volume":"119","author":"C Wolfram","year":"2022","unstructured":"Wolfram C, Schargus M. Das Hamburger Register f\u00fcr intravitreale Injektionstherapien (QIVOM). Ophthalmologe. 2022;119:280\u201387","journal-title":"Ophthalmologe"},{"key":"808_CR10","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00417-020-04798-2","volume":"258","author":"C Ehlken","year":"2020","unstructured":"Ehlken C, Ziemssen F, Eter N, Lanzl I, Kaymak H, Lommatzsch A, et al. Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol. 2020;258:2077\u201390","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"808_CR11","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/bjophthalmol-2015-308166","volume":"100","author":"FG Holz","year":"2016","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, et al. Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. 2016;100:1623\u201328","journal-title":"Br J Ophthalmol"},{"key":"808_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, Bora Eldem SJT, Hirst C, Paladini L, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128:234\u201347","journal-title":"Ophthalmology"},{"key":"808_CR13","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1055\/s-0041-107672","volume":"233","author":"HG Sachs","year":"2016","unstructured":"Sachs HG, Wilke R. Real-Life-Daten zur Anti-VEGF-Therapie: Therapieadh\u00e4renz bestimmt den Visuserhalt bei neovaskul\u00e4rer AMD. Klin Monatsbl\u00e4tter f\u00fcr Augenheilkunde. 2016;233:958\u201364","journal-title":"Klin Monatsbl\u00e4tter f\u00fcr Augenheilkunde"},{"key":"808_CR14","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/opo.13298","volume":"44.3","author":"R Munzar","year":"2024","unstructured":"Munzar R, Roh S, Ramsey DJ. Factors associated with loss to follow-up in patients with advanced age-related macular degeneration: a telehealth recall initiative. Ophthalmic Physiol Optics. 2024;44.3:626\u201333","journal-title":"Ophthalmic Physiol Optics"},{"key":"808_CR15","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12886-023-03018-9","volume":"23","author":"X Huang","year":"2023","unstructured":"Huang X, Zheng M, Lu J, et al. Analyze of factors and prognosis of eyes lost to follow-up in retinal vein occlusive disease patients receiving anti-vascular endothelial growth factor therapy. BMC Ophthalmol. 2023;23:262","journal-title":"BMC Ophthalmol"},{"key":"808_CR16","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1097\/IAE.0000000000001892","volume":"38","author":"M Weiss","year":"2018","unstructured":"Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina. 2018;38:2293\u2013300","journal-title":"Retina"},{"key":"808_CR17","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.4103\/ijo.IJO_1866_19","volume":"68","author":"A Kelkar","year":"2020","unstructured":"Kelkar A, Webers C, Shetty R, Kelkar J, Labhsetwar N, Pandit A, et al. Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol. 2020;68:2143\u201347","journal-title":"Indian J Ophthalmol"},{"issue":"12","key":"808_CR18","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s40123-024-01028-4","volume":"13","author":"BS Thinggaard","year":"2024","unstructured":"Thinggaard BS, Hansen K, Dinesen F, Pedersen MK, Mors\u00f8 L, Subhi Y, et al. The I-OPTA questionnaire: a national assessment of patients with neovascular age-related macular degeneration. Ophthalmol Ther. 2024, Dec;13(12):3035\u201346","journal-title":"Ophthalmol Ther"},{"key":"808_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-06925-3","author":"Y Lv","year":"2025","unstructured":"Lv Y, Zhu L, Li FH, Li H. Nonadherence to anti-VEGF intravitreal injections in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2025. https:\/\/doi.org\/10.1007\/s00417-025-06925-3. PMID: 41108384","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"808_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-025-01268-y","author":"B Warren","year":"2025","unstructured":"Warren B, Donohoe M, Sivaprasad S, Wykoff CC. Patient and Physician perspectives on the management of diabetic macular edema. Ophthalmol Ther. 2025. https:\/\/doi.org\/10.1007\/s40123-025-01268-y. PMID: 41239158.SUBHI und Soerens 2017","journal-title":"Ophthalmol Ther"},{"key":"808_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14040400","author":"P Kusenda","year":"2024","unstructured":"Kusenda P, et al. Understanding loss to follow-up in AMD patients receiving VEGF In-hibitor therapy. Diagnostics. 2024. https:\/\/doi.org\/10.3390\/diagnostics14040400. PMID: 38396439","journal-title":"Diagnostics"},{"key":"808_CR22","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1055\/s-0042-122340","volume":"235","author":"K Hufendiek","year":"2018","unstructured":"Hufendiek K, Pielen A, Framme C. Injektionsstrategien bei der Anwendung intravitrealer VEGF-Inhibitoren: \u201ePro Re Nata versus Treat and Extend\u201c. Klin Monbl Augenheilkd. 2018;235:930\u201339","journal-title":"Klin Monbl Augenheilkd"},{"key":"808_CR23","doi-asserted-by":"crossref","unstructured":"Debourdeau E, Beylerian H, Nguyen V, et al. Treat-and-extend versus Pro re nata regimens of Ranibizumab and Aflibercept in neovascular age-related macular degeneration: a comparative study from Routine Clinical Practice. Ophthalmol Ther. 2024;13:2343\u201355","DOI":"10.1007\/s40123-024-00983-2"},{"issue":"5","key":"808_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/08820538.2025.2467853","volume":"40","author":"Y Sun","year":"2025","unstructured":"Sun Y, Zhang W, Hu B, Sun B, Zhang T, Yu S, et al. Treat-and-Extend versus Pro Re Nata regimen of intravitreal conbercept injection for neovascular age-related macular degeneration: results from COCOA, a prospective, open-label, multicenter, randomized phase IV Clinical trial. Semin Ophthalmol. 2025;40(5):393\u201399","journal-title":"Semin Ophthalmol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00808-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00808-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00808-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:06:33Z","timestamp":1781633193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00808-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["808"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00808-3","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"This study complied with the Declaration of Helsinki and was approved by the regional ethics committee in D\u00fcsseldorf, Germany (approval date: June 28, 2021). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable; the manuscript contains no identifiable individual data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}